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Objective: We compared outcomes after treatment with direct oral anticoagulants (DOACs) and vitamin K antagonists
(VKAs) in patients with atrial ﬁbrillation (AF) and a recent cerebral ischemia.
Methods: We conducted an individual patient data analysis of seven prospective cohort studies. We included patients
with AF and a recent cerebral ischemia (<3 months before starting oral anticoagulation) and a minimum follow-up of
3 months. We analyzed the association between type of anticoagulation (DOAC versus VKA) with the composite primary
endpoint (recurrent ischemic stroke [AIS], intracerebral hemorrhage [ICH], or mortality) using mixed-effects Cox propor-
tional hazards regression models; we calculated adjusted hazard ratios (HRs) with 95% conﬁdence intervals (95% CIs).
Results: We included 4,912 patients (median age, 78 years [interquartile range {IQR}, 71–84]; 2,331 [47.5%] women;
median National Institute of Health Stroke Severity Scale at onset, 5 [IQR, 2–12]); 2,256 (45.9%) patients received VKAs
and 2,656 (54.1%) DOACs. Median time from index event to starting oral anticoagulation was 5 days (IQR, 2–14) for
VKAs and 5 days (IQR, 2–11) for DOACs (p = 0.53). There were 262 acute ischemic strokes (AISs; 4.4%/year), 71 intra-
cranial hemorrrhages (ICHs; 1.2%/year), and 439 deaths (7.4%/year) during the total follow-up of 5,970 patient-years.
Compared to VKAs, DOAC treatment was associated with reduced risks of the composite endpoint (HR, 0.82; 95% CI,
0.67–1.00; p = 0.05) and ICH (HR, 0.42; 95% CI, 0.24–0.71; p < 0.01); we found no differences for the risk of recurrent
AIS (HR, 0.91; 95% CI, 0.70–1.19; p = 0.5) and mortality (HR, 0.83; 95% CI, 0.68–1.03; p = 0.09).
Interpretation: DOAC treatment commenced early after recent cerebral ischemia related to AF was associated with
reduced risk of poor clinical outcomes compared to VKA, mainly attributed to lower risks of ICH.
ANN NEUROL 2019;85:823–834
Oral anticoagulation is effective in the prevention ofischemic stroke and systemic embolism in patients
with atrial ﬁbrillation (AF).1,2 Vitamin K antagonists
(VKAs) inhibiting the production of several coagulation
factors in the liver have been the only option for long-term
oral anticoagulation for many years.1 Direct oral anticoagu-
lants (DOACs) including the thrombin inhibitor, dabigatran,3
and the factor Xa inhibitors,4 apixaban, edoxaban, and
rivaroxaban, have been proven to be at least as effective in
preventing ischemic stroke and systemic embolism in patients
with AF while having a lower risk of symptomatic intracranial
hemorrhage (ICH).2,5–8 Patients with ischemic stroke and
AF are at high risk for early recurrent acute ischemic stroke
(AIS),9,10 which may be as high as 13% within the ﬁrst
10 days in patients not treated with oral anticoagulants.11
Among patients in the control (no treatment) groups of the
randomized International Stroke Trial, the rate of recurrent
AIS within the ﬁrst 14 days was still as high as 4.5% and
4.9%, respectively.12 Risk of ICH in this population, and
the effect of early anticoagulation, is unclear13: To mini-
mize the risk of ICH, all randomized controlled trials5–8
(RCTs) comparing DOAC and VKA in patients with AF
excluded patients with a recent ischemic stroke for arbitrary
time periods ranging from 7 to 14 days for mild stroke, up
to 3 to 6 months for severe strokes.11 Actually, in patients
with a history of ischemic stroke enrolled in one of the
RCTs,14–17 the delay between the stroke and enrollment in
the trial was rather long: In ROCKET-AF16 (Rivaroxaban-
once daily, oral, direct factor Xa inhibition compared with
vitamin K antagonism for prevention of stroke and Embo-
lism Trial in Atrial Fibrillation), median delay was 551 days,
and in ARISTOTLE15 (Apixaban for Reduction in Stroke
and Other Thromboembolic Events in Atrial Fibrillation),
only 33% of patients were enrolled within 1 year of stroke.
In clinical practice, DOACs are often commenced earlier
than in the aforementioned RCTs,13 yet little is known
about safety and effectiveness of this approach.18–25 Thus,
we compared the clinical beneﬁt of DOAC and VKA in
patients having AF with a recent ischemic stroke or tran-
sient ischemic attack (TIA).
Materials and Methods
Study Design
As a joint collaborative initiative of seven European and Japanese
prospective, observational cohort studies, we performed a pooled
individual patient data analysis combining data of all consecutive
patients in the participating studies. Three authors (D.J.S.,
S.T.E., and G.M.D.M.) searched PubMed and MEDLINE
between January 1, 2012 and July 2017, with the terms
“DOAC, VKA, atrial ﬁbrillation and stroke or TIA.” We selected
peer-reviewed prospective, observational studies published in
English based on real-life cohorts in which DOAC or VKA were
administered within 3 months after the index stroke or TIA.
The principal investigators of these studies were contacted and
invited to participate in a pooled individual patient data analysis.
All invited centers agreed to participate. The following studies
were included: the single center prospective cohort studies from
Verona/Italy,19 Erlangen/Germany,20 Basel/Switzerland (“Novel
oral anticoagulants in stroke patients”/NOACISP),23 and the
multicenter cohort studies “Early Recurrence and Cerebral Bleed-
ing in Patients With Acute Ischemic Stroke and Atrial Fibrillation”
(RAF21 and RAF-NOAC22; 29 centers in Europe and Asia), “The
Clinical Relevance of Microbleeds in Stroke study” (CROMIS-2;
79 centers in the UK and one in the Netherlands),26,27 and “The
Stroke Acute Management with Urgent Risk-factor Assessment and
Improvement-Non-Valvular Atrial Fibrillation Study” (SAMURAI-
NVAF; 18 centers in Japan).18,24,28 Details about the participating
studies can be obtained from Table 1 (collaborators are listed in Sup-
plementary Table 1). Study quality and risk of bias were critically
appraised based on the scheme suggested by the Cochrane collabora-
tion (“Tool to Assess Risk of Bias in Cohort Studies”; available at:
http://methods.cochrane.org/sites/methods.cochrane.org.bias) and
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the Newcastle-Ottawa Scale (available at: http://www.ohri.ca/
programs/clinical_epidemiology/oxford.asp) by two authors (D.J.S.
and G.M.D.M.). Disagreement between reviewers was resolved by
collegial discussion. Our analysis was conducted with respect to the
STROBE criteria for observational studies.29
Inclusion and Exclusion Criteria
We included patients with: (1) AIS (deﬁned as a focal neurologi-
cal deﬁcit with acute onset and presence of a corresponding
lesion on diffusion weighted [DWI] magnetic resonance imaging
[MRI] or, if no MRI was acquired, signs of early ischemic injury
on computed tomography [CT]) or TIA (deﬁned as an acute-onset
focal neurological deﬁcit of presumed ischemic origin without a
corresponding lesion on DWI or, if no MRI was acquired, lasting
less than 24 hours); (2) diagnosis of nonvalvular AF, either known
before the index event or detected after the event; (3) oral anti-
coagulation with DOAC or VKA, either continued (for those
already on anticoagulation on admission), started, or resumed
within 3 months after the index event; (4) prospective follow-up
for at least 3 months or longer after the index event for the pres-
ence or absence of (i) recurrent AIS, (ii) ICH, and (iii) death (any
cause). Patients who died before the ﬁrst planned follow-up
(ie, within the ﬁrst 3 months following the index event) were still
included in the study.
We excluded patients with (1) mechanical heart valves;
(2) rheumatic or severe mitral valve stenosis; and (3) oral anti-
coagulation started later than 3 months after the index event, or
with missing information on oral anticoagulants initiation date.
Data Collection and Baseline Data
Data were collected as done in previous published studies30,31:
Brieﬂy, local investigators ﬁlled in standardized forms with
predeﬁned variables using individual patient data from their
corresponding study database. Completed forms were collected
at the coordinating center in Basel, where the pooled analysis
was performed. The corresponding authors had full access to all
the data in the study and take responsibility for its integrity and
the data analysis.
Baseline Data
The following baseline variables were recorded and provided by
the participating studies: age, sex, and type of index event (AIS
or TIA); antithrombotic treatment (no treatment, antiplatelet
agents, VKA, or DOAC) before index event; type of anti-
coagulation after index event (VKA or DOAC), time from index
event to ﬁrst dose of VKA or DOAC; stroke severity on admis-
sion as assessed by the National Institutes of Health Stroke Scale
(NIHSS)32; and use of intravenous thrombolysis or endovascular
treatment for index stroke. DOAC therapy was deﬁned as one of
the following drugs and dosages: apixaban 2.5 or 5mg twice-daily
(bid); dabigatran 110 or 150mg bid; edoxaban 30 or 60mg once-
daily (od); or rivaroxaban 15 or 20mg od (10or 15mg od in Japan
according to the results from a domestic trial33). VKA therapy was
deﬁned as treatment with phenprocoumon (NOACISP, Erlangen)
or warfarin (SAMURAI-NVAF, CROMIS-2, RAF/RAF-DOAC,
and Verona). Choice of treatment was up to the decision of the
treating physician.
The following risk factors were collected: history of ischemic
stroke; history of ICH; diabetes mellitus; hypertension (deﬁned as
treated/controlled and untreated/uncontrolled hypertension);
hypercholesterolemia; impaired renal function (deﬁned as creati-
nine clearance of <60ml/min/1.73m2 using the Chronic Kidney
Disease Epidemiology Collaboration [CKD-EPI] equation34);
current smoking; concomitant use of antiplatelet drugs or sta-
tins; and the CHA2DS2-VASc
35 and HAS-BLED36 scores
(designed to predict future AIS and major bleeding complica-
tions, respectively).
TABLE 1. Single- and Multicenter Studies Participating in the Individual Patient Data Analysis
Study Period
Patients Contributed
to Final Cohort
Maximum Follow-up
Perioda
Single center
Verona (Italy)19 2013–2015 230 3-month
Erlangen (Germany)20 2011–2013 337 Up to 1 year
NOACISP (Basel/Switzerland)23 2012–2017 518 Up to 3.8 years
Multicenter
RAF (29 centers in Europe/Asia)21 2012–2014 572 3-month
RAF-NOAC (29 centers in Europe/Asia)22 2014–2016 963 3-month
SAMURAI-NVAF (18 centers in Japan)24 2011–2014 1,137 Up to 3.5 years
CROMIS-2 (80 centers in the UK and one in
the Netherlands)26
2011–2015 1,261 Up to 5.4 years
aMinimum follow-up period of 3 months for all studies.
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Follow-up
We included only studies with a planned follow-up of at least
3 months after index event for (1) recurrent AIS deﬁned as new
neurological symptoms and evidence for ischemic stroke on CT
or MRI, (2) ICH deﬁned as new neurological symptoms associated
with the detection of ICH on CT or MRI as deﬁned within the
International Society on Thrombosis and Haemostasis criteria,37
and (3) all-cause mortality (including fatal AIS or ICH). Interna-
tional normalized ratio (INR) values at outcome event in patients
on VKA was collected if available.
Outcome
The primary outcome was the occurrence of the composite end-
point of recurrent AIS, ICH, and mortality. Secondary endpoints
were the occurrence of each of these components separately.
Statistical Analysis
We compared demographic and clinical baseline characteristics
among patients in the two groups of anticoagulants using the
Pearson χ2 test for categorical variables and the Mann–Whitney
U test for continuous variables. An α-level of 0.05 was used to
determine statistical signiﬁcance. Statistical analyses were carried
out using R38 (R Foundation for Statistical Computing) and
SPSS software (Version 25; IBM Corp, Armonk, NY). We calcu-
lated the annualized rate of outcome events (=total of observed
events/patient-years of follow-up).
To assess the association between the type of anticoagulation
(DOAC versus VKA) and the primary composite endpoint, time to
endpoint, was modeled using a mixed-effects Cox proportional haz-
ards regression model to compute hazard ratios (HRs) with 95%
conﬁdence intervals (95% CIs). For competing risks of the second-
ary endpoints, the Fine-Gray model was used.39 For the primary
composite endpoint and for each secondary endpoint separately, we
compared time until the ﬁrst occurrence of an event. Only events
occurring after starting VKA or DOAC were used. Type of anti-
coagulation (DOAC versus VKA) was included as a ﬁxed effect.
The analysis was adjusted for age, NIHSS at onset, history of stroke
or TIA (ie, before the index event), history of ICH, sex, diabetes
mellitus, smoking, treatment with intravenous thrombolysis for
index event, and hypertension as ﬁxed effects.” Cohort Study Iden-
tiﬁer” (seven options) was included as a random effect. As a post-
hoc analysis, we further dichotomized the DOAC group into
DOACs with od intake (edoxaban and rivaroxaban, DOACod) and
those with bid intake (apixaban and dabigatran, DOACbid) and
compared them separately with VKA.
We assessed treatment effects in the following predeﬁned
subgroups: (1) patients with minor stroke or TIA (deﬁned as
NIHSS ≤3)40; (2) patients with severe stroke (deﬁned as
NIHSS >15)41; (3) elderly patients (deﬁned as aged ≥80 versus
<80 years); (4) patients with impaired renal function (deﬁned
as creatinine clearance of <60ml/min/1.73m2 using the CKD-EPI
equation34); (5) patients treated with acute recanalization therapies
for the index stroke (intravenous thrombolysis and/or endovascular
therapy); and (6) patients started on anticoagulation earlier than in
all phase-3 RCTs regarding the DOACs (≤7 versus >7 days after
index event).23 Thereby, each binary variable indicating a
subgroup was included in a separate model and the interac-
tion term between the covariate and the treatment was esti-
mated. Furthermore, the same covariates as described for the
main analysis were used as additional covariates. However, in
the models for the subgroups “minor stroke” and “severe
stroke,” NIHSS at onset was not used as a continuous covari-
ate because dichotomized NIHSS was already used to deﬁne
the subgroups. Similarly, the covariate age was replaced for the
subgroup of elderly patients when estimating the interaction term.
A signiﬁcant interaction term indicates that the estimated differ-
ence between treatments differs between the subgroups. The esti-
mated HRs are presented as forest plots. Missing values were not
imputed, and analyses were performed using only patients without
missing values in the relevant variables. However, as a sensitivity
analysis, we repeated the analysis using multiple imputation for
missing values42 using multivariate imputation by chained equa-
tions. Thereby, all available data were used as predictors for each
target variable (sometimes called massive imputation). In total, ﬁve
imputed data sets were constructed and analysed. The results were
pooled according to Rubin’s rule, using the Barnard-Rubin
adjusted degrees of freedom for small samples. In addition, we per-
formed a propensity-score-weighted (propensity score matching;
PSM) analysis using the R-package “twang.” Thereby, boosted
regression was used to estimate the propensity scores, including
the same variables as described for the main analysis. The mean
Kolmogorov-Smirnov statistic was used as balance criteria used to
tune the propensity score model. The composite endpoint as well
as each of its components (recurrent AIS, ICH, and mortality)
were presented in Kaplan-Meier curves and cumulative incidence
functions for competing risks.
Ethics
The NOACISP LONG-TERM registry and the current anal-
ysis of pooled individual patient data were approved by the
ethics committee in Basel, Switzerland (EKNZ 2014-027).
Patients provided written consent for participation in NOACISP
LONG-TERM. The requirement for additional local ethical
approval differed among participating centers and was acquired by
the local principal investigator as well as written informed consent
by the patient, if necessary. CROMIS-2 was approved by the
National Research Ethics Committee, London Queen Square.
Patients with capacity gave informed written consent. When
patients could not consent, we obtained written consent from a
proxy as deﬁned by relevant local legislation. The SAMURAI-
NVAF registry and the collaboration with the joint initiative were
approved by the ethics committee in the National Cerebral and
Cardiovascular Center (M23-18-3 and M29-077).
Results
The ﬁnal cohort comprised of 4,912 patients (see study
ﬂow chart Fig 1). Median age was 78 years (interquartile
range [IQR], 71–84) and 2,331 (47.5%) patients were
female. The index event was ischemic stroke in 4,739
patients (96.5%). Before the index event, 2,658 (54.1%)
patients had no antithrombotic treatment, 429 (8.7%)
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were on antiplatelet agents, 607 (12.4%) on VKA, and
1,153 (23.5%) on any DOAC. After the index event,
2,256 (45.9%) patients received VKA and 2,656 (54.1%)
received any DOAC. In the whole cohort, median time
from index stroke to start of oral anticoagulation was
5 days (IQR, 2–12). There was no difference in median time
from index stroke to starting oral anticoagulation between
patients receiving VKA (median, 5 days; IQR, 2–14) and
DOAC (median, 5 days; IQR, 2–11; p = 0.53). Overall,
3,993 patients (81.3%) were started on VKA or DOAC
within the ﬁrst 14 days after the index stroke. Overall, risk
of bias was medium to low (Supplementry Table 2). Only
one study19 (contributing 230 patients = 4.7% of the study
population) was at high risk of bias because it did not
include any patients on VKA (no controls).
Baseline Data and Demographics
Baseline data of the DOAC and VKA cohorts are displayed
in Table 2. To summarize, patients receiving DOACs had
a lower NIHSS at baseline, a lower prevalence of diabetes
mellitus, and more often received intravenous thrombolysis
for the index stroke. Patients treated with VKA were more
often current smokers.
Primary and Secondary Endpoints
Total follow-up time was 5,970 patient-years, 3,382 in
the VKA group, and 2,588 in the DOAC group. During
the entire follow-up (see Fig 2), 262 patients had AIS
(4.4%/year), 71 had ICH (1.2%/year), and 439 died
(7.4%/year). Figure 2 displays the Kaplan-Meier curves
for the primary composite endpoint and its components.
Overall, in 2,984 (61%) patients, the full data set of base-
line characteristics was available and these patients were
included in the main analysis. The following values were
missing: history of ICH (1,467 missing values), NIHSS
on admission (489 missing values), hypertension (22 miss-
ing values), diabetes mellitus (10 missing values), age
(eight missing values), history of stroke or TIA (two miss-
ing values), and sex (one missing value).
DOAC treatment was associated with a lower risk of
the composite primary outcome (HR, 0.82; 95% CI,
0.67–1.00; p = 0.05) compared with VKA (Table 3).
Patients receiving DOAC were also at lower risk of ICH
(HR, 0.42; 95% CI, 0.24–0.71; p < 0.01). Risk of recur-
rent AIS (HR, 0.91; 95% CI, 0.70–1.19; p = 0.5) and
mortality (HR, 0.83; 95% CI, 0.68–1.03; p = 0.09; all
Table 3) did not differ between DOAC and VKA
treatment.
The cumulative incidence function (Fig 3) does not
suggest clear evidence for competing risks. In general, the
highest hazard was the hazard for mortality. Patients
treated with VKA were at higher risk for all events.
Using multiple imputation, results for the primary
composite endpoint (HR, 0.85; 95% CI, 0.71–1.00;
p = 0.05) and the secondary analysis of ICH (HR, 0.34;
95% CI, 0.19–0.62; p < 0.01) remained signiﬁcant. No sta-
tistically signiﬁcant difference was observed between patients
with DOAC and VKA for risk of mortality (HR, 0.86; 95%
CI, 0.70–1.06; p = 0.17) and the risk of recurrent AIS (HR,
0.89; 95% CI, 0.68–1.18; p = 0.42). PSM analysis found a
signiﬁcant difference in the primary composite endpoint
(HR, 0.81; 95% CI, 0.70–0.93; p < 0.01), ICH (HR, 0.33;
95% CI, 0.19–0.58; p < 0.01), and mortality (HR, 0.72;
95% CI, 0.61–0.85; p < 0.01). Again, risk of recurrent AIS
(HR, 1.09; 95% CI, 0.86–1.38; p = 0.46) did not differ
between DOAC and VKA.
Post-Hoc Analysis
Among the 2,656 patients receiving a DOAC, 723 (27.2%)
took apixaban, 959 (36.1%) dabigatran, 11 (0.4%)
edoxaban, and 880 (33.1%) rivaroxaban, and in 83 patients
(3.1%), type of DOAC was not speciﬁed. Compared to
VKA, DOACbid (apixaban or dabigatran) was associated with
a reduced risk of the composite endpoint (HR, 0.63;
95% CI, 0.48–0.82; p < 0.01). DOACod (edoxaban or
rivaroxaban) had a lower hazard than VKA for the com-
posite endpoint, but this was not statistically signiﬁcant
(HR, 0.83; 95% CI, 0.64–1.08; p = 0.16). Both DOACod
and DOACbid were not associated with a reduced risk of
recurrent AIS (DOACod: HR, 1.39; 95% CI, 0.94–2.06;
FIGURE 1: Study ﬂow chart.
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p = 0.10; DOACbid: HR, 0.83; 95% CI, 0.55–1.28;
p = 0.41). Both DOACod and DOACbid were signiﬁ-
cantly associated with a reduced risk of ICH (DOACod:
HR, 0.25; 95% CI, 0.07–0.84; p = 0.02; DOACbid:
HR, 0.42; 95% CI, 0.18–0.97; p = 0.04) and mortality
(DOACod: HR, 0.70; 95% CI, 0.50–0.97; p = 0.03;
DOACbid: HR, 0.52; 95% CI, 0.37–0.73: p < 0.01).
Among patients with unknown type of DOAC (n = 83),
mortality was high (41 death). For patients on VKA having
recurrent AIS during follow-up (n = 137), information on
VKA at recurrent AIS was available in 65 patients (47.4%).
INR was <2.0 in 45 of these 65 patients (69.2%) and ≥2.0
in 20 (30.8%). In patients on VKA having ICH during
follow-up (n = 52), INR at ICH was available in 26 patients
(40.0%). INR was <2.0 in 13 patients (50.0%), 2.0 to 3.0
in 10 (38.5%), and >3.0 in 3 (11.5%).
Subgroup Analyses
Results for the predeﬁned subgroups are displayed in
Figure 4. There were signiﬁcant modiﬁcations of treatment
effect on the composite endpoint and mortality in patients
with impaired renal function in favor of DOACs. There
TABLE 2. Baseline Characteristics of Patients With DOAC and VKA Therapy
VKA n = 2,256 DOAC n = 2,656 p
Demographics
Age in years 78 (71–84) 77 (71–84) 0.17
Sex female 1,060 (47.0%) 1,274 (48.0%) 0.35
Index stroke
Acute ischemic stroke 2,178 (96.5%) 2,561 (96.4%) 0.82
TIA 78 (3.5%) 95 (3.6%)
NIHSS at onset 6 (2–16) 4 (2–10) <0.001**
Intravenous thrombolysis 385 of 2,192 (17.6%) 626 of 2,630 (23.8%) <0.001**
Endovascular treatment 89 of 2,256 (3.9%) 90 of 2,656 (3.4%) 0.30
Time from index stroke to start of
anticoagulation therapy (in days)
5 (2–14) 5 (2–11) 0.53
Risk factors
History of ischemic stroke (before index event) 544 of 2,255 (24.1%) 600 of 2,655 (22.6%) 0.21
History of intracranial hemorrhage 26 of 1,701 (1.5%) 19 of 1,744 (1.1%) 0.26
Diabetes mellitus 610 of 2,251 (27.1%) 596 of 2,651 (22.5%) <0.001**
Hypertension 1,669 of 2,242 (74.4%) 2,002 of 2,648 (75.6%) 0.35
Hypercholesterolemia 842 of 2,208 (38.1%) 739 of 1,826 (40.5%) 0.13
Impaired renal functiona 529 of 1,717 (30.8%) 530 of 1,748 (30.3%) 0.78
Current smoking 325 of 2,213 (14.7%) 456 of 2,571 (17.7%) 0.04*
CHA2DS2-Vasc 5 (4–6) 5 (4–6) 0.43
HAS-BLED 3 (3–4) 3 (2–4) 0.21
Concomitant antiplatelet agents 826 of 2,073 (39.8%) 826 of 2,207 (37.4%) 0.10
Concomitant statins 230 of 935 (24.6%) 280 of 1,036 (27.0%) 0.22
Categorical variables are given in number of patients having the characteristic/total patients available for analysis and (%).
Continuous variables are displayed in median (interquartile range).
aImpaired renal function deﬁned as creatinine clearance of <60ml/min/1.73m2.
*p < 0.05; **p < 0.001.
TIA = transient ischemic attack; NIHSS = National Institute of Health Stroke Severity Scale.
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were no signiﬁcant interactions between overall treatment
effects in the other predeﬁned subgroups.
Discussion
This individual patient data analysis of seven international,
independent cohort studies including 4,912 patients
treated with oral anticoagulation after recent cerebral
ischemia related to AF revealed the following major ﬁnd-
ings: First, treatment with DOACs commenced a median
of 5 days after the index event has a lower risk of adverse
outcomes compared to treatment with VKA; second, this
beneﬁt is mainly attributed to lower risks of ICH; and,
third, the beneﬁt is consistent across subgroups, including:
those with either minor (NIHSS ≤3) or severe (NIHSS
>15) strokes at baseline; those aged 80 years or older; those
started on anticoagulants ≤7 days since index stroke; and
those treated with acute recanalization therapies for the
index stroke.
Our pooled data provide the largest available data set
of best-practice stroke unit patients with AF and recent cere-
bral ischemia treated with DOAC or VKA for secondary
prevention. Subgroup analyses from the large RCTs compar-
ing DOACs and VKAs showed consistent results in patients
with a history of ischemic stroke compared to the overall trial
population,14–17 but patients with an ischemic stroke were
excluded from these RCTs for at least 7 to 14 days and up
to 3 to 6 months because of concerns of hemorrhagic trans-
formation.11 In ARISTOTLE7 (comparing apixaban with
VKA), 19% of all patients had history of ischemic stroke
and only 33% were included within 1 year after index
stroke.15 In ROCKET-AF8 (comparing rivaroxaban with
VKA), where 55% of all patients had a history of previous
ischemic stroke, the median time from stroke to enrollment
in the trial was 551 days.16 To the best of our knowledge,
no information on the delay between ischemic stroke and
trial enrollment is available for RE-LY (Randomized Evalu-
ation of Long-term Anticoagulation Therapy)5,14 (compar-
ing dabigatran with VKA, 20% of patients had a history of
ischemic stroke) or ENGAGE-TIMI AF 48 (Effective Anti-
coagulation With Factor Xa Next Generation in Atrial
Fibrillation–Thrombolysis in Myocardial Infarction 48)6,17
(comparing edoxaban with VKA, 28% of patients had a
FIGURE 2: Kaplan-Meier curves for the composite endpoint (A), recurrent AIS (B), ICH (C), and mortality (D) for patients in
both groups (VKA vs DOAC). AIS = acute ischemic stroke; DOAC = direct oral anticoagulant; ICH = intracranial hemorrhage;
VKA = vitamin K antagonist. [Color ﬁgure can be viewed at www.annalsofneurology.org]
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history of ischemic stroke). By contrast with RCTs, all
patients in our cohort had a recent ischemic stroke within
the last 3 months preceding the start of anticoagulation and
81% within 14 days. The median delay of just 5 days in
both—patients receiving DOAC and those receiving
VKA—means that 80% of our patients would not have
been eligible for any of the pivotal RCTs.43
We can only speculate on the reasons for the appar-
ent beneﬁt of DOAC therapy in patients with a recent
ischemic stroke and AF, but it might be related to the
increased risk of ICH and mortality,9,10 making them
ideal candidates for DOAC therapy. A post-hoc analysis
found that the reduced risk of ICH—and mortality—was
consistent across different types of DOACs (od and bid
intake). For the risk of AIS, neither DOACbid nor
DOACod were signiﬁcantly superior to VKA. However,
only DOACbid, but not DOACod, were associated with a
signiﬁcantly reduced risk of the composite endpoint com-
pared to VKA. We urge caution not to overinterpret these
ﬁnding. Despite multivariate analysis, residual con-
founding is likely to account for the differences in these
nonrandomized comparisons. In patients on VKA, 70%
of the recurrent AISs occurred in patients with INR <2.0
whereas only 10% of the ICH occurred in patients with
INR >3.0. A recent study found that in patients on
rivaroxaban with ICH, rivaroxaban plasma levels were
high in only 25% of the patients.44 These ﬁndings under-
line that other causes of ICH beyond anticoagulant activ-
ity (ie, small vessel disease) might play an important role
in ICH associated with the use of oral anticoagulants.
Our interaction analysis showed that the timing of
initiation of oral anticoagulation (≤7 versus >7 days) did
not signiﬁcantly modify the association between the type
of oral anticoagulation (DOAC versus VKA) and the end-
points. The lower risk of ICH under DOAC compared to
VKA treatment was therefore not modiﬁed by the timing
of initiation of anticoagulation. This aligns with our previ-
ous ﬁndings showing that an early start of DOAC (≤7 days
from index stroke) is associated with a low risk of ICH.23
However, the timing of initiation of oral anticoagulation
still remains unclear and is being investigated in ongoing
controlled clinical trials.
Our new analyses expand on the previous observa-
tions by exploring the effects of DOACs compared to
VKAs across different subgroups. We have shown that the
overall beneﬁt of DOACs in patients with a recent ischemic
stroke are consistent in patients with both minor and major
FIGURE 3: Cumulative incidence function. DOAC = direct
oral anticoagulant; VKA = vitamin K antagonist.
TABLE 3. Primary and Secondary Outcomes in Patients Taking DOAC Compared To Patients Taking VKA
VKA n = 2,256 DOAC n = 2,656 HR (95% CI) p
Primary outcome
Composite endpointa 485 events/3,207
patient-years (15.1%/y)
272 events/2,479
patient-years (11.0%/y)
0.82 (0.66–1.00) 0.05
Secondary outcomes
Recurrent AIS 137 events/3,229
patient-years (4.2%/y)
110 events/2,484
patient-years (4.4%/y)
0.91 (0.70–1.19) 0.5
ICH 52 events/3,302
patient-years (1.6%/y)
22 events/2,549
patient-years (0.9%/y)
0.42 (0.24–0.71) <0.01
Mortality 358 events/3,324
patient-years (10.8%/y)
161 events/2,556
patient-years (6.3%/y)
0.83 (0.68–1.03) 0.09
Given as number of events and total follow-up time (annualized event rate).
aComposite endpoint: acute ischemic stroke (AIS), intracranial hemorrrhage (ICH), and mortality.
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stroke, patients treated with acute recanalization therapies
for the index event, and in older patients. These ﬁndings
are reassuring, because patients with major strokes and of
older age might have an increased a priori risk of ICH and
mortality that could be aggravated by anticoagulation.
Interestingly, we found evidence of a potential additional
beneﬁt of DOAC therapy in patients with impaired renal
function. In this subgroup, use of low-dose DOACs might
have contributed to reduced risks of ICH and mortality,
but this remains speculative. Whether the potential beneﬁcial
effect of DOACs in patients with impaired renal function is
explained by the over-representation of patients with severely
impaired renal function (<30ml/min) in the VKA group
(given that this is a contraindication for DOAC therapy)
needs to be further studied. We therefore emphasize caution
in the interpretation of our results.
Our study has the following strengths: (1) We con-
ducted an individual patient data analysis of seven interna-
tional studies involving patients from Europe and Asia,
which makes our results broadly generalizable; (2) we report
FIGURE 4: Subgroup analyses of treatment effect in predeﬁned subgroups for the composite endpoint (A), recurrent AIS (B), ICH
(C), and mortality (D). AIS = acute ischemic stroke; DOAC = direct oral anticoagulant; HR = hazard ratio; ICH = intracranial
hemorrhage; NIHSS = National Institute of Health Stroke Severity Scale; VKA = vitamin K antagonist. [Color ﬁgure can be
viewed at www.annalsofneurology.org]
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on a large data set of patients with a recent ischemic stroke
currently available with nearly 5,000 patients and a total
follow-up time of 5,970 patient-years; (3) all participating
studies prospectively recruited stroke patients (in the major-
ity of cases consecutively) minimizing selection bias;
(4) both cohorts—VKA and DOAC patients—had a com-
parable size of 2,500 patients each, a comparable delay
between index stroke and start of anticoagulation of only
5 days, and were well balanced in most of the known risk
factors and demographics; and (5) sensitivity analysis using
PSM and cumulative incidence function did not identify
competing risks and using multiple imputation for missing
variables conﬁrmed the main ﬁndings of our study—a
reduced risk of the composite endpoint as well as a reduced
risk of ICH. The reduced risk of ICH and mortality com-
pared to VKA was consistent among all types of DOACs
(od and bid).
Nevertheless, our study has some limitations: (1) We
report on an observational, nonrandomized study rather
than a randomized trial. Allocation to the type of oral anti-
coagulant is likely to be affected by biases that cannot be
fully adjusted for, and the results have to be interpreted
with great caution; RCTs need to provide further data on
the risks and beneﬁts of early start of DOACs in patients
with AF. (2) Reasons for the choice of the type of anti-
coagulation and, in case of DOAC treatment, for the use of
a speciﬁc agent were not recorded; it is likely that these
choices were inﬂuenced by unmeasurable factors related to
the individual physician’s decision, which might have
inﬂuenced our key ﬁndings. (3) Although most risk factors
and baseline characteristics were well balanced between
patients receiving VKA and DOAC, there were signiﬁcant
differences between both cohorts with patients on DOACs
having a lower baseline NIHSS, a higher treatment rate of
intravenous thrombolysis, and lower prevalence of diabetes.
Although we adjusted for these characteristics, residual con-
founding by patient characteristics that were not measured
in these cohorts cannot be ruled out (ie, patients’ choice,
compliance and adherence with treatment). (4) Extracranial
(ie, gastrointestinal) bleeding events have been found to be
more frequent in patients taking DOACs.2 Collection of
extracranial bleeding events and cause of death were heterog-
enous among the participating studies, and we therefore
refrained from analyzing this data. (5) The majority of
patients on DOACs received dabigatran, rivaroxaban, or
apixaban. Only a minority of patients were treated with
edoxaban, which limits the validity of our results for
edoxaban. (6) In a minority of patients (3.1%), the type of
DOAC was unknown, and this subgroup had a higher mor-
tality than the rest of the cohort. (7) We did not collect
information on time in therapeutic range for patients on
VKA. Patients on VKA having recurrent AIS had
subtherapeutic (<2.0) INR values in 70% of the cases, indi-
cating that poor compliance is a potential factor. However,
INR was supratherapeutic (>3.0) in only 10% of the patients
having ICH. (8) Finally, we did not account for therapy
changes during follow-up that might have inﬂuenced our
results.
Currently, several RCTs are investigating the risks
and beneﬁts of early start of DOACs13 (Switzerland: ELAN
ClinicalTrials.gov Identiﬁer: NCT03148457; Sweden:
TIMING ClinicalTrials.gov Identiﬁer: NCT02961348;
UK: OPTIMAS: EudraCT, 2018-003859-38 and USA:
START ClinicalTrials.gov Identiﬁer: NCT03021928). Our
ﬁndings support these trials, which do not compare
DOACs with VKAs, but will give further insights into what
is the optimal time point to start DOACs after a recent
stroke. The results of our study underline the importance
of RCTs further investigating early timing of DOACs in
patients with AF and a recent ischemic stroke.
To summarize, our study provides class IIa and level
B evidence that DOAC therapy commenced early after a
recent ischemic stroke in patients with AF is beneﬁcial
compared to VKA therapy. This beneﬁt is driven by a
decreased risk of ICH.
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